Track the Mereo BioPharma Group plc share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €54.7m. The latest transaction was reported on 16 September 2024 (Cession). Among the most active insiders: Hughes-Wilson Alexandra. All data is openly available.
24
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€539,820
10 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Mereo BioPharma Group plc Buy (bullish), based on 5 analysts. Average price target: US$1.98.
59Σ signal
Buys n/a€539,820 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,500 of 29,053 companies
24.3
score / 100
Value
3
Quality
46
FCF yld-57%
Earn yld-77%
EV/EBITDA·
ROE-76%
Gross mgn73%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
93,333 shares@ US$1.4064.5% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-24-064274:0
24 of 24 declarations
About Mereo BioPharma Group plc
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing treatments for rare diseases and age-related disorders. It is listed on NASDAQ under the ticker symbol MREO.